For the first time, the issue of access to medicine for patients is known and understood even at the level of the prime minister.
In Conversation
The reason we are looking at data is that the therapies that are being developed are much more targeted and specific than ever before. For example,…
Romania has the infrastructure and the people and has the potential to play a competitive role when it comes to clinical trials in Europe. Unfortunately, the…
Compared to other countries, we have a very dense network of specialized clinics with high-quality clinical equipment, where all administrative work is completed on advanced service…
In the long run, healthcare will absolutely have to move to digitalization. In my opinion, perhaps the biggest hurdle is that the stakeholders here in Belgium…
We are a medtech company, but we also have pharma-like products like lubricants and eye drops. For more than 70 years, Alcon has focused exclusively on…
Even though lab animals make up only a limited portion of the total cost of new drug development, they are very important for every R&D process…
If you want to build a startup, you must have skin in the game, not only be a passive investor sitting in an office; you need…
[Belgium is] somewhat less bureaucratic than other European countries in the overall process of research and innovation. Therefore, we manage to be competitive in achieving research…
The MENA region is key for Novartis because it currently produces USD 1.4 billion in sales for the company
Ultimately, even if a country has the best primary care system, patients would still require specialty care. Primary and specialty care need to be integrated within…
Across the healthcare continuum, there really is no other neutral, global, interdisciplinary organization that covers the breadth of science, technology, and policy – whether it is…
